Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease

Behavioural Pharmacology

Volumn 21, Issue 3, 2010, Pages 194-205

  Kreisler, Alexandre ^a   Duhamel, Alain ^a   Vanbesien Mailliot, Christel ^a   Destée, Alain ^a   Bordet, Régis ^a  

^a UNIV LILLE   (France)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 6 hydroxydopamine; Bezafibrate; Fenofibrate; Parkinson's disease; Peroxisome proliferator activated receptor

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; BEZAFIBRATE; FENOFIBRATE; OXIDOPAMINE;

ACTIMETRY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; MOTOR ACTIVITY; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; SENSITIZATION;

EID: 77953124810     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833a5c81     Document Type: Article

References (54)

1. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al. (1997). Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12:25-31.
2. Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C (2005). Fenofibrate, a peroxysome proliferator-activated receptor a agonist, exerts neuroprotec-tive effects in traumatic brain injury. Neurosci Lett 388:7-12.
3. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001). Molecular pathway involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172.
4. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC (1997). Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94:3363-3367.
5. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, et al. (2006). PPAR: a new pharmacological target for neuroprotection in stroke and neuro-degenerative diseases. Biochem Soc Trans 34:1341-1346.
6. Bové J, Prou D, Perier C, Przedborski S (2005). Toxin-induced models of Parkinson's disease. NeuroRx 2:484-494.
7. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002). Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82:615-624.
8. Conover WJ, Iman RL (1981). Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 35:124-129.
9. Crawley JN (1999). Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835:18-26.
10. Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB (1998). Distribution of mRNAs encoding the peroxysome proliferator-activated receptor a, b, and g and the retinoid X receptor a, b, and g in rat central nervous system. J Neurochem 70:1366-1375.
11. Cuzzocrea S, Mazzon E, Di Paola S, Peli A, Bonato A, Britti D, et al. (2006). The role of the peroxysome proliferator-activated receptor-a (PPAR-a) in the regulation of acute inflammation. J Leukocyte Biol 79:999-1010.
12. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004). Protection with pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88:494-501.
13. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. (1999). Peroxysome proliferator-activated receptor alpha negatively regulates the inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Biol Chem 274:32048-32054.
14. Deplanque D, Gelé P, P étrault O, Six I, Furman C, Bouly M, et al. (2003). Peroxisome proliferator-activated receptor-a activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264-6271.
15. Deumens R, Blokland A, Prickaerts J (2002). Modeling Parkinson's disease in rats: an evaluation of the 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317.
16. Dexter DT, Carter CJ, Wells FR, Agid F, Agid Y, Lees A, et al. (1989). Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
17. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992). Control of peroxisomal beta-oxidation pathway by a novel family of nuclear receptors. Cell 68:879-887.
18. Frederiksson A, Palomo T, Chase T, Archer T (1999). Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists. J Neural Tr a n s m 106:283-300.
19. Fruchart JC, Duriez P, Staels B (1999). Peroxisome proliferator-activated receptors regulate gene governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245-257.
20. Gonzalez FJ, Shah YM (2008). PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246:2-8.
21. Greenamyre JT, Sherer TB, Betarbet R, Panov AV (2001). Complex I and Parkinson's disease. IUBMB Life 52:135-141.
22. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, et al. (2000). Caspase 3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97:2875-2880.
23. Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, et al. (2001). Caspase-8 is an effector in apoptotic death of dopamine neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21:2247-2255.
24. Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, Gimble JM (1999). Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun 67:3488-3493.
25. Hirsch EC, Hunot S, Damier P, Faucheux B (1998). Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann Neurol 44:S115-S120.
26. Hofele K, Sedelis M, Auburger GW, Morgan S, Huston JP, Schwarting RK (2001). Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp Neurol 168:116-122.
27. Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996). Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363.
28. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50:3-11.
29. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995). Time course and morphology of dopaminergic neuronal death caused by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
30. Johannessen JN, Adams JD, Schuller HM, Bacon JP, Markey SP (1986). 1-Methyl-4-phenylpyridine (MPP +) induces oxidative stress in the rodent. Life Sci 38:743-749.
31. Kreisler A, Gelé P, Wiart JF, Lhermitte M, Destée A, Bordet R (2007). Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 1135:77-84.
32. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W (1997). Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxysome proliferator-activated receptors by coactivator-depen-dent receptor ligand assay. Mol Endocrinol 11:779-791.
33. Lee JH, Joe EH, Jou I (2005). PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. Neuroreport 16:829-833.
34. Mally P, Mishra R, Gandhi S, Decastro MH, Nankova BB, Lagamma EF (2004). Stereospecific regulation of tyrosine hydroxylase and proenkephalin genes by short-chain fatty acids in rat PC12 cells. Pediatr Res 55: 847-854.
35. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999). PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131.
36. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291.
37. Melis M, Pillolla G, Luchicchi A, Muntoni AL, Yasar S, Goldberg SR, Pistis M (2008). Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 28:13985-13994.
38. Mutez E, Duhamel A, Defebvre L, Bordet R, Destée A, Kreisler A (2009). Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol Res 60:41-45.
39. Pahan K, Jana M, Liu X, Taylor BS, Wood C, Fischer SM (2002). Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem 277:45984-45991.
40. Paxinos G, Watson C, editors (1986). The rat brain in stereotaxic coordinates. San Diego: Academic Press.
41. Poynter ME, Daynes RA (1999). Age-associated alterations in splenic iNOS regulation: influence of constitutively expressed IFN-gamma and correction following supplementation with PPARalpha activators or vitamin E. Cell Immunol 195:127-136.
42. Przedborski S, Jackson-Lewis V (1998). Mechanisms of MPTP toxicity. Mov Disord 13 (Suppl 1):35-38.
43. Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD (1998). Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 19:43-48.
44. Schwarting RK, Sedelis M, Hofele K, Auburger GW, Huston JP (1999). Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res 1:41-56.
45. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000a). MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:1 71-182.
46. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000b). Evidence for resistance to MPTP in C57BL/6 x BALB/c F1 hybrids as compared with their progenitor strains. Neuroreport 11:1093-1096.
47. Sedelis M, Schwarting RKW, Huston JP (2001). Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-122.
48. Swanson CJ, Kalivas PW (2000). Regulation of locomotor activity by metabo-tropic glutamate receptors in the nucleus accumbens and ventral tegmental area. J Pharmacol Exp Ther 292:406-414.
49. Teismann P, Schulz JB (2004). Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318:149-161.
50. Ungerstedt U (1971). Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-91.
51. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, et al. (2002). Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarction size. FASEB 16:1027-1040.
52. Xu J, Storer PD, Chavis JA, Racke MK, Drew PD (2005). Agonists for the peroxysome proliferator-activated receptor-a and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 81:403-411.
53. Xu J, Chavis JA, Racke MK, Drew PD (2006). Peroxysome proliferator-activated receptor-a and retinoid X receptor agonists inhibit inflammatory response of astrocytes. J Neuroimmunol 176:95-105.
54. Zahm DS (2000). An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav R 24:8-105.